Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13542039 | 0.89 | ALDH1A1 (0.58) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL13539392 | 0.89 | ALDH1A1 (0.63) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL11202055 | 0.88 | ALDH1A1 (0.73) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL13539382 | 0.84 | ALDH1A1 (0.58) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL6930554 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL6930563 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL3485204 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL8094638 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL3485202 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNATSHRSMN1; SMN2HPGD | |
| SCHEMBL17097394 | 0.82 | ALDH1A1 (0.62) | ALDH1A1LMNATSHRSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223163-A1 | CARBON NITRIDES WITH HIGHLY CRYSTALLINE FRAMEWORK AND PROCESS FOR PRODUCING SAME | THE UNIVERSITY OF NEWCASTLE (AU) | 2025-07-10 | — | — | US | claimed |
| EP-4565367-A1 | CARBON NITRIDES WITH HIGHLY CRYSTALLINE FRAMEWORK AND PROCESS FOR PRODUCING SAME | The University of Newcastle (AU) | 2025-06-11 | — | — | EP | claimed |
| WO-2025083112-A1 | RUBBER COMPOSITIONS COMPRISING A SPECIFIC CROSSLINKING SYSTEM | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2025-04-24 | — | — | WO | claimed |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | claimed |
| EP-4293035-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2023-12-20 | — | — | EP | claimed |
| CN-116888136-A | Method for preparing oligonucleotides | 味之素株式会社 | 2023-10-13 | — | — | CN | claimed |
| WO-2023010175-A1 | CARBON NITRIDES WITH HIGHLY CRYSTALLINE FRAMEWORK AND PROCESS FOR PRODUCING SAME | THE UNIVERSITY OF NEWCASTLE (AU) | 2023-02-09 | — | — | WO | claimed |
| WO-2022172994-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | 味の素株式会社 | 2022-08-18 | — | — | WO | claimed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | claimed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | claimed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | claimed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | claimed |
| US-9281000-B2 | Photopolymer formulation for producing visible holograms | COVESTRO DEUTSCHLAND AG (DE) | 2016-03-08 | — | — | US | claimed |
| EP-2372454-A1 | Photopolymer formulation for producing visible holograms | Bayer MaterialScience AG (DE) | 2011-10-05 | — | — | EP | claimed |
| US-20110236803-A1 | PHOTOPOLYMER FORMULATION FOR PRODUCING VISIBLE HOLOGRAMS | BAYER MATERIALSCIENCE AG (DE) | 2011-09-29 | — | — | US | claimed |
| US-7393395-B2 | Surface-treating agent for metal | NIPPON MINING & METALS CO., LTD. (JP) | 2008-07-01 | — | — | US | claimed |
| US-5840294-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-11-24 | — | — | US | claimed |
| EP-0777966-B1 | Disulfide stabilizers for 3-isothiazolones | ROHM & HAAS (US) | 1998-05-13 | — | — | EP | claimed |
| US-5230982-A | Heterocyclic disulfides for crosslinking | THE MEAD CORPORATION (US) | 1993-07-27 | — | — | US | claimed |
| US-20250223163-A1 | CARBON NITRIDES WITH HIGHLY CRYSTALLINE FRAMEWORK AND PROCESS FOR PRODUCING SAME | THE UNIVERSITY OF NEWCASTLE (AU) | 2025-07-10 | — | — | US | disclosed |
| EP-4565367-A1 | CARBON NITRIDES WITH HIGHLY CRYSTALLINE FRAMEWORK AND PROCESS FOR PRODUCING SAME | The University of Newcastle (AU) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025083112-A1 | RUBBER COMPOSITIONS COMPRISING A SPECIFIC CROSSLINKING SYSTEM | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025083112-A1 | RUBBER COMPOSITIONS COMPRISING A SPECIFIC CROSSLINKING SYSTEM | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2025-04-24 | — | — | WO | disclosed |
| US-20240336711-A1 | REAGENTS AND METHODS FOR ALIPHATIC CARBON-HYDROGEN BOND FUNCTIONALIZATION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2024-10-10 | — | — | US | disclosed |
| US-20240174865-A1 | COATING COMPOSITIONS COMPRISING A POLYSULFIDE CORROSION INHIBITOR | PRC-DESOTO INTERNATIONAL, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-11993862-B2 | Structure including copper plating layer or copper alloy plating layer | ISHIHARA CHEMICAL CO., LTD. (JP) | 2024-05-28 | — | — | US | disclosed |
| US-11939691-B2 | Tin or tin alloy electroplating bath, and electronic component having electrodeposit formed thereon using the plating bath | ISHIHARA CHEMICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4293035-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2023-12-20 | — | — | EP | disclosed |
| CN-116888136-A | Method for preparing oligonucleotides | 味之素株式会社 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023010175-A1 | CARBON NITRIDES WITH HIGHLY CRYSTALLINE FRAMEWORK AND PROCESS FOR PRODUCING SAME | THE UNIVERSITY OF NEWCASTLE (AU) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022241129-A1 | REAGENTS AND METHODS FOR ALIPHATIC CARBON—HYDROGEN BOND FUNCTIONALIZATION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022172994-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | 味の素株式会社 | 2022-08-18 | — | — | WO | disclosed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190189932-A1 | TRANSPARENT ELECTRODE AND ELECTRONIC DEVICE | Konica Minolta, Inc. (JP) | 2019-06-20 | — | — | US | disclosed |
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10062657-B2 | Method for manufacturing alloy bump | ISHIHARA CHEMICAL CO., LTD. (JP) | 2018-08-28 | — | — | US | disclosed |
| US-20170330850-A1 | METHOD FOR MANUFACTURING ALLOY BUMP | ISHIHARA CHEMICAL CO., LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| US-9818962-B2 | Organic electroluminescent element and method for manufacturing same | Konica Minolta, Inc. (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9818962-B2 | Organic electroluminescent element and method for manufacturing same | Konica Minolta, Inc. (JP) | 2017-11-14 | — | — | US | disclosed |
| EP-3206225-A1 | METHOD FOR MANUFACTURING ALLOY BUMP | Ishihara Chemical Co., Ltd. (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20170110677-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND METHOD FOR MANUFACTURING SAME | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170110677-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND METHOD FOR MANUFACTURING SAME | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170005295-A1 | LIGHT EXTRACTION LAYERED BODY, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND METHOD FOR MANUFACTURING SAME | Konica Minolta, Inc. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170005295-A1 | LIGHT EXTRACTION LAYERED BODY, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND METHOD FOR MANUFACTURING SAME | Konica Minolta, Inc. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| WO-2016069438-A1 | STABLE TRANSPARENT CONDUCTIVE ELEMENTS BASED ON SPARSE METAL CONDUCTIVE LAYERS | C3NANO INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122562-A1 | STABLE TRANSPARENT CONDUCTIVE ELEMENTS BASED ON SPARSE METAL CONDUCTIVE LAYERS | C3NANO INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122562-A1 | STABLE TRANSPARENT CONDUCTIVE ELEMENTS BASED ON SPARSE METAL CONDUCTIVE LAYERS | C3NANO INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122562-A1 | STABLE TRANSPARENT CONDUCTIVE ELEMENTS BASED ON SPARSE METAL CONDUCTIVE LAYERS | C3NANO INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160111676-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT | Konica Minolta, Inc. (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20160111676-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT | Konica Minolta, Inc. (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9281000-B2 | Photopolymer formulation for producing visible holograms | COVESTRO DEUTSCHLAND AG (DE) | 2016-03-08 | — | — | US | disclosed |
| US-20150287953-A1 | TRANSPARENT ELECTRODE, ELECTRONIC DEVICE, AND ORGANIC ELECTROLUMINESCENT ELEMENT | Konica Minolta, Inc. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20150287953-A1 | TRANSPARENT ELECTRODE, ELECTRONIC DEVICE, AND ORGANIC ELECTROLUMINESCENT ELEMENT | Konica Minolta, Inc. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8642801-B2 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| EP-2372454-A1 | Photopolymer formulation for producing visible holograms | Bayer MaterialScience AG (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20110236803-A1 | PHOTOPOLYMER FORMULATION FOR PRODUCING VISIBLE HOLOGRAMS | BAYER MATERIALSCIENCE AG (DE) | 2011-09-29 | — | — | US | disclosed |
| CN-101498002-B | Surface-treating method for metal, treated metal surface and printed wiring substrate | NIPPON MINING CO | 2011-06-22 | — | — | CN | disclosed |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-05-06 | — | — | US | disclosed |
| CN-1914356-B | Surface treatment agent for metal | NIPPON MINING CO | 2010-05-05 | — | — | CN | disclosed |
| CN-101498002-A | Surface-treating agent for metal and printed wiring substrate | NIKKO MATERIALS CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-7393395-B2 | Surface-treating agent for metal | NIPPON MINING & METALS CO., LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| US-7311893-B2 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20070157845-A1 | Surface-treating agent for metal | JX NIPPON MINING & METALS CORPORATION (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1781098-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-7184198-B2 | Display element | KONICA MINOLTA HOLDINGS, INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7184198-B2 | Display element | KONICA MINOLTA HOLDINGS, INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| CN-1914356-A | Surface treatment agent for metal | NIKKO MATERIALS CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-7148001-B2 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | UNIVERSITY OF WASHINGTON (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2006015317-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1614432-A2 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-11 | — | — | EP | disclosed |
| EP-1609467-A1 | Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions | Neurochem (International) Limited (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-6943268-B2 | Method for induction of L-selectin shedding | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | disclosed |
| US-20040096453-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-05-20 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-20030092763-A1 | Method for induction of L-selectin shedding | SCIENCE & TECHNOLOGY CORPORATION @UNM | 2003-05-15 | — | — | US | disclosed |
| US-6498189-B1 | SUPPRESSION OF INFLAMMATION AND OF LYMPH NODE ENTRY BY CALMODULIN ANTAGONISTS; CELL ASSOCIATED PROTEIN DISULFIDE ISOMERASE INHIBITORS; P-AMINOPHENYLARSINE OXIDES | UNIVERSITY OF NEW MEXICO | 2002-12-24 | — | — | US | disclosed |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | QUEEN'S UNIVERSITY | 2002-12-19 | — | — | US | disclosed |
| US-20020168753-A1 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | NATIONAL INSTITUTES OF HEALTH | 2002-11-14 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | disclosed |
| US-6310073-B1 | ADMINISTERING TO SUBJECT THERAPEUTICALLY EFFECTIVE AMOUNT OF 3-AMINO-1-PROPANESULFONIC ACID, OR PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, SUCH THAT GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTION IS MODULATED AND CONDITION IS TREATED | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-30 | — | — | US | disclosed |
| US-5840294-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-11-24 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| US-4546075-A | TETRAZOLE, BENZOTHIAZOLE, BENZOXAZOLE, OR BENZIMIDAZOLE COMPOUNDS | FUJI PHOTO FILM CO., LTD. (JP) | 1985-10-08 | — | — | US | disclosed |
| US-4452885-A | USING THRIHALOMETHYL-3,4-OXADIAZOLES AS ANTIFOGGING AGENTS | FUJI PHOTO FILM CO., LTD. (JP) | 1984-06-05 | — | — | US | disclosed |
| US-4186012-A | NON-DIFFUSIBLE THIOETHER RELEASES DIFFUSIBLE MERCAPTAN, SILVER HALIDE | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1980-01-29 | — | — | US | disclosed |
| US-4171223-A | DEVELOPMENT INHIBITOR COMPRISING A 1,2,5-THIADIAZOLINE-1,1-DIOXIDE COMPOUND | AGFA-GEVAERT, A.G. (DE) | 1979-10-16 | — | — | US | disclosed |
| US-4088491-A | COLOR PHOTOGRAPHY, THIOETHERS, NONDIFFUSING | AGFA-GEVAERT AKTIENGESELLSCHAFT (DT) | 1978-05-09 | — | — | US | disclosed |
| US-4088491-A | COLOR PHOTOGRAPHY, THIOETHERS, NONDIFFUSING | AGFA-GEVAERT AKTIENGESELLSCHAFT (DT) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336711-A1 | REAGENTS AND METHODS FOR ALIPHATIC CARBON-HYDROGEN BOND FUNCTIONALIZATION | NCF1, SHROOM3, NPM1 | ALDH1A1 2010/4885LMNA 2104/4885TSHR 3045/4885 |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | HIF1AN, HBG2, HIF1A | ALDH1A1 2214/4885LMNA 4829/4885TSHR 3096/4885 |
| US-10251392-B2 | Antimicrobial devices and compositions | AAAS, AOC1, COL14A1 | ALDH1A1 178/4885LMNA 4430/4885TSHR 4664/4885 |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | ALDH1A1 178/4885LMNA 4430/4885TSHR 4664/4885 |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | ALDH1A1 3305/4885LMNA 1379/4885TSHR 4314/4885 |
| US-20040096453-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | ALDH1A1 2097/4885LMNA 2106/4885TSHR 2787/4885 |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | ALDH1A1 3305/4885LMNA 1379/4885TSHR 4314/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ALDH1A1 2989/4885LMNA 71/4885TSHR 4779/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | ALDH1A1 1880/4885LMNA 2481/4885TSHR 3280/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ALDH1A1 2989/4885LMNA 71/4885TSHR 4779/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | ALDH1A1 2097/4885LMNA 2106/4885TSHR 2787/4885 |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ALDH1A1 2989/4885LMNA 71/4885TSHR 4779/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | ALDH1A1 2504/4885LMNA 380/4885TSHR 3417/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ALDH1A1 3131/4885LMNA 89/4885TSHR 4731/4885 |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | ALDH1A1 1880/4885LMNA 2481/4885TSHR 3280/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | ALDH1A1 2989/4885LMNA 71/4885TSHR 4779/4885 |
| US-20030092763-A1 | Method for induction of L-selectin shedding | PDIA5, PDIA4, PDIA6 | ALDH1A1 1261/4885LMNA 4121/4885TSHR 4422/4885 |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | HIF1AN, HBG2, HIF1A | ALDH1A1 2214/4885LMNA 4829/4885TSHR 3096/4885 |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, NOX4, POLRMT | ALDH1A1 1227/4885LMNA 4781/4885TSHR 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.